Literature DB >> 1920700

Pseudomalabsorption of levothyroxine.

K B Ain1, S Refetoff, H G Fein, B D Weintraub.   

Abstract

OBJECTIVE: --The issue of patient compliance with pharmacological therapy vs malabsorption of medication was explored in the context of persistent hypothyroidism despite the administration of large doses of levothyroxine sodium.
DESIGN: --Retrospective case series.
SETTING: --Referred care in two large tertiary care centers. PATIENTS: --Four patients, seen within two decades, with clinical and biochemical hypothyroidism while receiving levothyroxine, were evaluated for selective malabsorption of this hormone.
INTERVENTIONS: --Studies included serial measurements of thyroid hormone levels after a loading dose of levothyroxine or liothyronine sodium or evaluation with a double-labeled thyroxine tracer technique. Results were compared with studies of levothyroxine malabsorption in the medical literature.
RESULTS: --All patients were ultimately found to have normal (82% to 100%) absorption of oral levothyroxine. There was no evidence that malabsorption of levothyroxine can occur as an isolated abnormality.
CONCLUSIONS: --Some patients exhibit a factitious disorder suggesting malabsorption of levothyroxine. When treating hypothyroidism, psychiatric issues may result in noncompliance with levothyroxine therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1920700

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  21 in total

Review 1.  Controversial aspects of thyroid disease.

Authors:  F W Hanna; J H Lazarus; M F Scanlon
Journal:  BMJ       Date:  1999-10-02

2.  Increased levothyroxine requirements presenting as "inappropriate" TSH secretion syndrome in a patient with nephrotic syndrome.

Authors:  M T Collins; A T Remaley; G Csako; F Pucino; M C Skarulis; J E Balow; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2000-06       Impact factor: 4.256

3.  Pseudomalabsorption of Levothyroxine: A Challenge for the Endocrinologist in the Treatment of Hypothyroidism.

Authors:  Nancy Van Wilder; Bert Bravenboer; Sarah Herremans; Nathalie Vanderbruggen; Brigitte Velkeniers
Journal:  Eur Thyroid J       Date:  2016-11-24

4.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

5.  The TRHR Gene Is Associated with Hypothalamo-Pituitary Sensitivity to Levothyroxine.

Authors:  Giulia Brigante; Giorgia Spaggiari; Daniele Santi; Katia Cioni; Valentina Gnarini; Chiara Diazzi; Elisa Pignatti; Livio Casarini; Marco Marino; Frank Tüttelmann; Cesare Carani; Manuela Simoni
Journal:  Eur Thyroid J       Date:  2014-06-07

6.  Levothyroxine pseudo-malabsorption: testing and treatment in the outpatient setting.

Authors:  Grzegorz M Rdzak; Laura M Whitman; Silvio E Inzucchi
Journal:  Ther Adv Endocrinol Metab       Date:  2018-04-28       Impact factor: 3.565

7.  Levothyroxine absorption test results in patients with TSH elevation resistant to treatment.

Authors:  Ilgin Yildirim Simsir; Utku Erdem Soyaltin; Ahmet Gokhan Ozgen
Journal:  Endocrine       Date:  2019-03-13       Impact factor: 3.633

Review 8.  Thyroid hormone therapy for hypothyroidism.

Authors:  Bernadette Biondi; David S Cooper
Journal:  Endocrine       Date:  2019-08-01       Impact factor: 3.633

9.  Once weekly thyroxine treatment as a strategy to treat non-compliance.

Authors:  S Rangan; A A Tahrani; A F Macleod; P K Moulik
Journal:  Postgrad Med J       Date:  2007-10       Impact factor: 2.401

10.  Timing of levothyroxine administration affects serum thyrotropin concentration.

Authors:  Thien-Giang Bach-Huynh; Bindu Nayak; Jennifer Loh; Steven Soldin; Jacqueline Jonklaas
Journal:  J Clin Endocrinol Metab       Date:  2009-07-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.